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Abbreviations
CVD  Cardiovascular disease
tAF  Total active fraction
ACE  Angiotensin-converting enzyme
EPA  Eicosapentaenoic acid, 20:5n-3
TRAP  Thrombin receptor-activating peptide
DHA  Docosahexaenoic, 22:6n-3
WSTC  Water-soluble tomato concentrate
EFSA  European Food Safety Authority
PDI  Protein disulphide isomerase
TF  Tissue factor
PRP  Platelet-rich plasma
VSMC  Vascular smooth muscle cells
TxA2  Thromboxane A2
Introduction
During the last 50 years, tomato (Lycopersicon esculentum) 
has become a highly consumed healthy food [1]. Tomato 
contains several components that are beneficial to overall 
health, including vitamin E, flavonoids, phytosterols, carot-
enoids, several water-soluble vitamins and minerals [2]. 
The presence of a variety of antioxidants such as polyphe-
nols, e.g. quercetin, kaempferol, naringenin, and carote-
noids, in considerable amounts makes tomato a rich source 
of antioxidants [3, 4]. Since oxidative stress triggers inflam-
matory disorders, the basis for the development of several 
diseases such as immune disorders, atherosclerotic lesions 
Abstract Hyperactive platelets, in addition to their roles 
in thrombosis, are also important mediators of atherogen-
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and rupture of plaque [5], antioxidants present in tomato 
are therefore believed to slow the progression of many dis-
eases including cardiovascular disease (CVD). In order for 
tomato to provide cardio-protection, it must include bioac-
tive factors that are able to reduce several cardiovascular 
risk factors such as LDL cholesterol, triglycerides, homo-
cysteine, platelet hyperactivity and blood pressure [6].
Platelets play an important role in CVD both in the 
pathogenesis of atherosclerosis and in the development 
of acute thrombotic events (Fig. 1). Their importance in 
CVD is indirectly confirmed by the benefit of antiplatelet 
agents such as aspirin, clopidogrel and glycoprotein IIb/IIIa 
inhibitors abciximab/eptifibatide [7]. In fact, intravascular 
thrombosis is a factor in the generation of a wide variety of 
CVDs. Platelets in individuals with diabetes, sedentary life-
style, obesity and insulin resistance show increased activity 
at baseline and in response to agonists, ultimately leading 
to increased aggregation and plaque development [8–10]. 
Aspirin remains a cornerstone of antiplatelet therapy but 
does not benefit all patients equally, as evidenced by the 
phenomenon of aspirin resistance [7]. Aspirin therapy is 
also responsible for a number of serious side effects, ren-
dering it unsuitable for use in primary prevention of CVD 
[11, 12]. However, very few new antithrombotics are cur-
rently progressing beyond phase II trials, and those that 
have been developed are similarly unsuitable for use in 
primary prevention [12]. There is an interest in naturally 
occurring compounds which might lack the side effects 
currently so prevalent. We therefore systematically inves-
tigated the effects of bioactive compounds in fruits and 
vegetables on human blood platelet aggregation and uti-
lized the findings to characterize the mechanisms involved 
in this process, in the hope of identifying potential dietary 
antiplatelet components. In a variety of studies, it was 
demonstrated that water-soluble components of tomatoes 
are capable of inhibiting platelet aggregation both in vitro 
and in vivo [13–16]. These water-soluble tomato compo-
nents were also found to inhibit angiotensin-converting 
enzyme (ACE) and to relax the vascular endothelium, the 
other important limbs of the cardiovascular system [17, 
18]. A water-soluble tomato extract containing all the bio-
active components was developed and later given the trade 
name Fruitflow®. Fruitflow® is now an established natu-
rally derived functional food ingredient, marketed globally. 
Since its discovery in 1999, several mechanistic studies and 
human trials with Fruitflow® have been carried out. Stud-
ies included localization of the antiplatelet activity within 
the tomato fruit, its modes of action, its stability under vari-
ous conditions and identification of the compounds with 
antiplatelet activity. The presence of a range of compounds 
suggested that all have antiplatelet activity but act on differ-
ent parts of the platelet activation/aggregation pathway. The 
chemical properties of the active compounds indicated their 
potential suitability as therapeutic agents or as functional 
food ingredients. There are several excellent reviews avail-
able on overall health benefits of tomatoes [1, 2, 4, 5, 19, 
20]. This review will discuss the background to Fruitflow® 
discovery and the body of biological and regulatory work 
involved in the granting of its authorized health claim in 
Europe and acceptance as a functional food by regulatory 
authorities worldwide.
Epidemiology of tomato consumption and CVD 
risk reduction
Epidemiologic studies focused on tomato and tomato prod-
ucts associated their intake with a reduced risk of CVD [19, 
21, 22]. However, tomatoes and tomato-based products are 
important dietary sources of lycopene in observational stud-
ies, and most human lycopene trials are performed using 
tomato-based interventions. Studies showed that increased 
Pathological Disorders 
(Insulin resistance, 
Diabetes, hyperlipideamia, Ageing smoking, 
sedentary life style, High fat diets etc. ) 
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CVD events 
Coronary heart disease 





Fig. 1  Hyperactivity of platelets and impact on health. Platelets play 
an important role in CVD both in the pathogenesis of atherosclero-
sis and in the development of acute thrombotic events. Hyperactive 
platelets are involved in the development of atherosclerosis by dif-
ferent mechanisms such as membrane shedding, growth factor secre-
tion and expression of several adhesive factors. In addition, hyperac-
tive platelets are involved in the well-known penultimate thrombotic 
events
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plasma lycopene levels were associated with reductions in 
CVD risk factors [23–25]. The strongest population-based 
evidence for the beneficial effects of tomato lycopene came 
from a multi-centre case–control study [26]. However, a 
subsequent dietary intervention study observed that con-
sumption of a carotenoid-rich diet did not have an effect 
on plasma antioxidant status or markers of oxidative stress 
[27]. Several [25, 28], but not all [28–32] prospective stud-
ies relating circulating lycopene concentrations and CVD 
risk have reported inverse associations, while studies based 
on dietary intake did not find any such significant associa-
tions [32–36]. Also, the focus on lycopene in tomatoes can-
not explain the fact that, taking tomato consumption into 
account, individuals in the Mediterranean area have a lower 
risk of CVD when compared to their North American and 
other European counterparts [2, 37, 38]. Thus, it is difficult 
to separate out the potential lycopene contribution to cardi-
ovascular health from the overall contribution from tomato 
products and other components present in tomatoes. The 
lack of coherence between available epidemiological data 
and dietary intervention data underscores the requirements 
for further studies to unravel other non-lycopene com-
ponents in tomato and their roles in CVD risk reduction. 
Tomatoes contain several known and unknown compounds 
that might affect platelet function, lipid metabolism, blood 
pressure and endothelial function, important determi-
nants of CVD [5, 39]. Lycopene or other antioxidants act 
through inhibition of LDL oxidation alone and so may only 
partly contribute to the CVD risk reduction. Recent stud-
ies showed that tomato also contains gamma-aminobutyric 
acid, 13-oxo-9,11-octadecadienoic acid and esculeoside A, 
which may provide heart and psychological health benefits 
[40]. 13-oxo-ODA is, however, found only in tomato juice 
[41]. Esculeoside A reduces plasma lipids and therefore 
may ameliorate atherosclerotic lesions in ApoE-deficient 
mice [42]. This indicates that other unidentified compounds 
(non-lycopene compounds) may also contribute to the car-
dio-protective effects of tomatoes as observed in epidemio-
logical and interventional studies.
Role of platelet hyperactivity in the development 
of CVD
Platelet activity is thought to play a major role in the devel-
opment as well as the stability of atherosclerotic plaques. 
Abnormal activation of blood platelets might represent a 
contributory risk factor for accelerated vascular disease, 
which occurs in hypertension, because it plays an impor-
tant role in the development and progression of athero-
sclerosis [43]. In support of the pathophysiological role of 
platelets, platelet inhibitory drugs such as aspirin have been 
observed to reduce the incidence of myocardial infraction, 
stroke and death from CVD in secondary prevention trials 
[11, 43]. The pathophysiological state of platelets (hyper-
active) is the underlying risk of problems in diabetes, 
smoking, obesity and sedentary lifestyle and other condi-
tions (Table 1). Although the mechanism of the increase in 
platelet reactivity is uncertain in these conditions, it could 
be caused by sensitization of platelets to aggregation by 
elevated levels of agonists in vivo [44], or it could be due 
to the redistribution of young, more reactive platelets that 
are concentrated in the spleen [45] and are released into 
the systemic circulation. Platelets are activated by a large 
number of agonists that are released in the circulation dur-
ing some pathologic conditions (e.g. hypertension and 
diabetes mellitus) [46]. Several lines of evidence point to 
an important role for platelets in the pathogenesis of sud-
den death, acute myocardial infarction and unstable angina 
[47]. Other evidence supporting a causal role of local plate-
let activation in the pathogenesis of acute coronary events 
comes from studies demonstrating that aspirin, an inhibi-
tor of platelet thromboxane A2 (TxA2) synthesis, reduces 
the incidence of acute myocardial infarction and of cardiac 
death in patients with unstable angina. Recently, aspirin’s 
antiplatelet limitations have progressively underscored 
the critical need for improved platelet aggregation inhibi-
tor therapy which is not only effective, but also safe and 
well tolerated [11, 48, 49]. This concept has stimulated 
research into prevention of platelet hyperactivity by sev-
eral means including dietary supplementation. Develop-
ment of the atheroma is a gradual process, understood to 
be influenced by well-established traditional risk factors, 
including (but not limited to) hypertension, cigarette smok-
ing, diabetes mellitus, dyslipidemia and a family history of 
premature atherosclerotic disease. Considerable investiga-
tion into the pathophysiological effects induced by these 
factors has elucidated their contributions to the prothrom-
botic milieu within the atherosclerotic coronary artery 
Table 1  Hyperactivity of platelets related to disease
Platelets become hyperactive or produce circulating micro-aggregates 
in the clinically defined conditions shown
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preceding an atherothrombotic event. Activated platelets 
release different growth factors (e.g. PDGF and VEGF) 
that participate in the development of atherosclerosis by 
promoting VSMC proliferation [50]. Stimulated platelets 
release VEGF [51], and elevated VEGF levels have been 
found in patients with atherosclerotic risk factors such 
as hypertension [52]. Tests of platelet function have been 
used to investigate a possible role of platelet hyper-reac-
tivity in the pathogenesis of vascular disorders and their 
complications. Platelet activation and aggregation are also 
involved in the development of hypertension in different 
ways. Activated platelets release different mediators, such 
as 5-hydroxytryptamine (5-HT or serotonin), ADP, ATP 
and lysophosphatidic acid [50]. A number of these agents 
enhance the intracellular Ca2+ concentration ([Ca2+]i) in 
vascular smooth muscle cells (VSMC), which promotes 
vasoconstriction and increases catecholamines response. 
Furthermore, the number of platelet α-adrenergic receptors 
increases in hypertensive persons [53], which may promote 
catecholamines responses. Catecholamines, β-adrenoceptor 
agonist isoprenaline and angiotensin II (Ang II) increase 
[Ca2+]i and promote contraction of VSMC, platelet acti-
vation and aggregation [53] which may participate in the 
genesis and maintenance of hypertension. Moreover, it has 
been shown that Ang II increases [Ca2+]i and pH in plate-
lets from hypertensive patients, which may be associated 
with enhanced platelet aggregation [54]. In hypertension, 
platelets showed spontaneous aggregation and increased 
sensitivity to agonists [55, 56]. Furthermore, platelets 
release more β-thromboglobulin and P-selectin and have 
higher intracellular Ca2+ levels [57, 58]. Hypertension is 
associated with oxidative stress [57]. Thus, in hypertensive 
patients, platelets produce more reactive oxygen species 
which enhance platelet activity by reducing the bioavail-
ability of nitric oxide (NO) and enhancing [Ca2+]i among 
other cellular effects. Platelets are directly influenced by 
specific adipokines and therefore have the potential to serve 
as an essential mediator of the cardiovascular consequences 
of obesity. Consistent with this, obesity has been associated 
with increases in platelet aggregation, elevations in surface 
expression of markers of platelet activation such as P-selec-
tin and heightened platelet microparticle formation. More 
importantly, reduction in adipose mass leads to normaliza-
tion of markers of enhanced platelet activation. However, 
a causal role for platelet hyperactivation in obesity-related 
cardiovascular disorders remains to be established. Several 
characteristics and proven biological activities of platelets 
make them an appealing candidate for triggering and main-
taining the inflammatory response of obesity. Activated, 
but not resting platelets are able to alter the chemotactic 
properties of endothelial cells by inducing the secretion 
of monocyte chemoattractant protein. Similarly, trans-
forming growth factor-β is released from activated platelet 
α-granules and has been shown to augment the release of 
type-1 plasminogen activator inhibitor from adipose tissue. 
Importantly, a recent report indicates that the recruitment of 
inflammatory cells in adipose tissue is facilitated by plate-
let adhesion along activated endothelium. Based on these 
observations, it seems that platelet activation, secondary to 
obesity, plays a causal role in triggering and maintaining 
the pro-inflammatory and pro-thrombotic state of obesity, 
creating a feedback loop involving adipose tissue, acti-
vated platelets and vascular endothelium that culminates in 
an environment favourable for atherothrombotic vascular 
events [59, 60]. Therefore platelet activation contributes to 
the inflammatory and thrombotic consequences of obesity. 
All the data indicate the importance of taming platelets in 
order to avoid CVD.
In vitro studies with water‑soluble tomato extract 
on human blood platelet aggregation
The antiaggregatory effects of different aqueous fruit 
extracts on human platelets in vitro have been published 
previously [13]. The maximum inhibitory effect (70–
75 %) was found to be with tomato and kiwi fruit extracts, 
whereas apple and pear had very little activity (2–5 %). 
Grapefruit, melon and strawberry had intermediate activi-
ties on platelet aggregation (33–44 %). The antiplatelet 
potential of the fruits tested appeared to have no relation-
ship with their antioxidant activity [13]. These antiplate-
let compounds in tomato had a molecular mass less than 
1000 Da and were highly water soluble and stable to boil-
ing. The compounds of interest were concentrated into an 
aqueous extract produced by homogenizing fresh toma-
toes, removing particulate matter and delipidating. The 
delipidated aqueous extract was then further fractioned by 
gel filtration using a Biogel P2 column [13]. Adenosine, 
a known antiplatelet factor, was identified in one fraction, 
but its removal from the whole extract did not substantially 
decrease the antiplatelet activity, indicating the presence 
of additional, different antiplatelet agents. Further work 
showed that the aqueous tomato extract consisted largely 
of soluble sugars (85–90 % of dry matter), which showed 
no in vitro antiplatelet activity [15]. The non-sugar mate-
rial that was isolated (tomato total active fraction, tAF) 
accounted for 4 % of the aqueous tomato extract dry mat-
ter and showed strong inhibition of platelet aggregation 
in vitro. Isolation of many individual components from tAF 
followed, and it was found that most fell into one of three 
categories—nucleosides, simple phenolic derivatives and 
flavonoid derivatives. All showed antiplatelet activities con-
sistent with their compound categories.
Proteomic experiments carried out to examine effects 
of tAF on platelet signalling pathways showed that tAF 
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components altered a range of platelet functions including 
those regulating platelet structure, coagulation and redox 
status (Fig. 2). One of the most strongly affected proteins 
was protein disulphide isomerase (PDI), an oxidoreduc-
tase which catalyses the formation and the isomerization 
of disulphide bonds. In platelets, blocking PDI with inhibi-
tory antibodies inhibits a number of platelet activation 
pathways, including aggregation, secretion and fibrinogen 
binding [61, 62]. Other investigators [63] have reported 
similar functional effects after blockage of cell surface thiol 
isomerases. Glycosides related to quercetin, of which sev-
eral are present in tAF [O’Kennedy N. Fruit extracts. Inter-
national Patent WO 2010/049707, May 06, 2010], have 
been shown to interact with PDI in this way [64, 65]. Inter-
action of polyphenols with PDI suggested a possible mech-
anism by which tomato extract components could inhibit 
different pathways of platelet aggregation.
The functional effects of tAF components were there-
fore examined in a series of experiments. tAF and its sub-
fractions F1, F2 and F3, prepared by semi-preparative 
reversed-phase HPLC as described by O’Kennedy et al 
2006 [66], were observed to prevent activation of integrin 
αIIbß3 (ie, GPIIb/IIIa). Inhibition of the GPIIb/IIIa activa-
tion step—which is common to multiple aggregation path-
ways—could underlie the wide-ranging effects of tAF [15]. 
This is consistent with the observation that basal platelet 
cyclic AMP concentrations (controlled by phospholipase C 
enzyme family-mediated cascade reactions) are unaltered 
by tomato extract active components in vitro. In addition, 
tAF reduced the expression of P-selectin (CD62P) on the 
platelet surface in response to ADP-induced platelet activa-
tion in whole blood [15, 66]. In resting platelets, P-selectin 
is localized in the membranes of platelet α-granules. On 
platelet activation, it is redistributed to the platelet surface, 
where it initiates adhesion to leucocytes. Under conditions 
of blood flow and shear stress, this glycoprotein promotes 
platelet cohesion and stabilizes newly formed aggregates. 
Thus, tAF components can potentially affect the size and 
longevity of platelet aggregates. tAF components were also 
found to affect the binding of tissue factor (TF) to acti-
vated platelets, at least in part due to effects on P-selectin 
[O’Kennedy N and Song H-J. Therapeutic uses of tomato 
extracts. International Patent WO 2007/141495, December 
13, 2007].
In summary, these results demonstrating the actions of 
tAF on different platelet functions were all consistent with 
potential effects mediated partly through polyphenols and 
PDI and partly through nucleosides elevating cAMP and 
cGMP levels in platelets [13, 67]. Effects on TF binding 
suggested that tAF components could have a larger effect 
on some aspects of the coagulatory response, such as 
thrombin generation, than previously imagined. Figure 3 
summarizes the actions of different ingredients of Fruit-
flow® on platelet activation pathway.
Development of Fruitflow®: Compositional 
and structural aspects
To develop prototype plant-derived antiplatelet extracts in 
the laboratory requires understanding of the extract com-
ponents and the structure–function relationships affecting 
their mechanism of action and potency. These details were 
largely established for aqueous tomato extracts during an 
exploratory research phase as discussed earlier. However, 
to move from the laboratory prototype to a standardized 
food ingredient required a change in focus to extract repro-
ducibility, cost analysis and development of a rigorous 
Fig. 2  Effects of Fruitflow® on 
the platelet proteome. Classes 
of protein showing statisti-
cally significant changes after 
treatment with Fruitflow® at 
a concentration of 43 mg L−1 
(maximum theoretical circulat-
ing concentration after ingestion 
of a single 3 g/150 mg dose 
equivalent to 65 mg tAF or 
approximately three bowls of 
tinned tomato soup)
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quality assurance system capable of standardizing bioac-
tivity and controlling raw material variation, processing-
induced effects and multiple sites of manufacture. Focusing 
on these points developed the small-scale laboratory-grade 
aqueous tomato extract into a commercial food grade 
tomato extract, which was given the trade name Fruitflow®.
Today, Fruitflow® is made in two ingredient formats. 
The raw material for both formats is high grade, minimally 
processed tomato commodity products. Fruitflow® 1 is a 
syrup of which more than 50 % w/w comprises tomato-
derived carbohydrates, and ~3 % w/w comprises known 
bioactive compounds with measured antiplatelet activ-
ity. This ingredient format is especially suitable for use in 
drinks and foods with high water content. Fruitflow® 2 is 
a low-carbohydrate powder, of which more than 55 % w/w 
comprises bioactive compounds, dried to produce a tablet-
grade powder. Fruitflow® 2 can be compressed into tablets 
and has flow properties which render it suitable for cap-
sule formation or for use in dry-blend food processes. Both 
ingredient formats are lycopene- and fat-free, low in inor-
ganic salts and low in organic acids. The potency of Fruit-
flow® 1, in terms of bioactive compound content/g, is lower 
than that of Fruitflow® 2, as a consequence of their differ-
ent sugar content: relative potencies of the two ingredients 
when compared w/w are in an approximate ratio of 1:20. 
Thus, 3 g Fruitflow® 1 gives an equivalent dose of bioac-
tives (approximately 65 mg) to 150 mg Fruitflow® 2. Of 
this quantity, 6–10 % (up to 9 mg) are known nucleoside 
Fig. 3  Platelet activation via multiple pathways and sites of action 
of Fruitflow® ingredients. Key agonists, their receptors and trigger-
ing signalling pathways involved in platelet activation and subsequent 
aggregation. VWF von Willebrand factor, TXA2 thromboxane-A2, TP 
thromboxane receptor, ADP adenosine diphosphate, PAR proteinase-
activated receptor, PDI protein disulphide isomerase, TF tissue fac-
tor. The activation of platelets is accompanied by a conformational 
change in integrin aIIbb3 (glycoprotein (GP) IIb–IIIa), exposing 
a binding site for fibrinogen and triggering the release of aggregat-
ing agents such as TXA2 and ADP. Adenosine nucleotides signal 
through P2 purinergic receptors (P2Y) on the platelet membrane. 
Activation of these receptors initiates a complex signalling cascade 
that ultimately results in platelet activation, aggregation and thrombus 
formation. Thrombin acts via cell surface protease-activated recep-
tors (PARs). Both stimulate PLC giving rise to PIP2 hydrolysis and 
consequent activation of PI3K. Collagen acts both through recep-
tors (GPIV) and on integrin a2b1, promoting adhesion and trigger-
ing inside-out signalling. Inside-out signalling alters platelet skeletal 
characteristics to allow spreading and microparticle release, lead-
ing to increase in pro-coagulant potential. Inside-out signalling also 
exposes PDI on the platelet surface, which can alter the pro-coagulant 
potential of TF in situ, or alternatively transfer to endothelial cells. 
Fruitflow components have been shown to affect ADP, collagen, 
thrombin and TXA2-mediated signalling, to affect integrin activation 
and subsequent fibrinogen binding, and to down-regulate platelet PDI
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derivatives (F1), 13–15 % (up to 10 mg) are known phe-
nolic conjugates (F2), and 8–10 % (up to 7 mg) are known 
flavonoid derivatives (F3), including a minimum of 2.4 mg 
quercetin derivatives per dose. This amount of bioactive 
compounds, which comprises a single daily dose, is equiv-
alent to that found in about 3 average servings of tinned 
tomato soup.
The development of a quality assurance system which 
allows such standardization began with the implementation 
of an analytical HPLC system simple enough to run on the 
factory floor, but precise enough to measure selected impor-
tant antiplatelet compounds through each process step. The 
individual bioactivity profiles of compounds occurring in 
Fruitflow® were examined, and three representative com-
ponents, one from each of the three broad fractions F1, F2 
and F3 (as discussed earlier, these fractions were originally 
defined by reverse-phase HPLC fractionation, described in 
[15]), were selected. These three compounds were adeno-
sine, which represents a group of nucleosides/nucleotides 
found in F1, chlorogenic acid, which represents a group 
of phenolic derivatives found in F2, and rutin, which rep-
resents a group of flavonoid derivatives found in F3. The 
representative compounds were monitored throughout 
the developing process, from raw material to final prod-
uct; losses in any one of them would reflect losses of the 
entire class of compounds each represented and could be 
quantified and assessed. In addition, total tAF content was 
quantified throughout. The data collected were mapped 
onto bioactivity (antiplatelet activity) and the validity of 
the measurements as a method of monitoring overall bio-
activity established. The use of this bioactivity-led analysis 
then facilitated selection of suitable raw materials, control 
of raw material variability and investigation of the effects 
of thermal processing on bioactivity of extracts produced.
The presence within tomatoes of such a range of struc-
turally different water-soluble secondary metabolites 
reflects both the complex sensory profile of the tomato and 
its response to stresses. Many of the bioactive compounds 
are produced in the tomato fruit as part of the plant defences 
against insect or bacterial challenges. However, as tomatoes 
are grown under a wide range of conditions worldwide, a 
similarly wide variability in secondary metabolite composi-
tion might be expected. Table 2 shows the content of anti-
platelet compounds (tAF) in tomato juice and the overall 
antiplatelet activities of the juice, from a range of differ-
ent cultivars, geographical sources and degrees of ripeness. 
While tomatoes from different geographical locations and 
of different cultivars did show differences in the quantity 
of antiplatelet compounds extracted, the degree of ripeness 
of the tomatoes appears to be the most important factor in 
determining bioactivity. Thus, ripeness of tomatoes at the 
time of harvest became a key quality assurance factor in the 
development of the Fruitflow® food ingredients.
The type of processing undergone by fresh tomato fruit 
determines the extent to which the original antiplatelet activ-
ity of the fresh fruit can be retained. High-temperature pro-
cessing and/or long holding times at moderate–high tem-
peratures are detrimental to the antiplatelet activities of final 
products. Table 3 shows the tAF quantified in a range of pro-
cessed tomato foods. Many of the products tested displayed 
a very low tAF content and a correspondingly low bioactiv-
ity. It became evident from this work that control of tempera-
ture and time at temperature during processing was a key 
to retaining bioactivity in any process attempting to make a 
Table 2  Influence of tomato cultivar and ripeness on yield and antiplatelet activity of tAF
Cultivars were largely selected from typical processing cultivars for the region, but one fresh market cultivar was included. Quantities are given 
as mean values ± SEM
Source Cultivar Ripeness tAF isolated  
(mg/kg tomato fresh wt)
tAF IC50 against ADP 
agonist (mg/mL PRP)
UK Fresh market cultivar (greenhouse grown) Green 212 ± 50 10.8
Fully ripe 533 ± 35 <1.0
Processing cultivar E6203 (greenhouse 
grown)
Green 251 ± 64 15.6
Fully ripe 600 ± 77 <1.0
Spain Processing cultivar Green 377 ± 35 13.9
Fully ripe 745 ± 43 <0.5
Processing cultivar Green 352 ± 65 15.9
Fully ripe 698 ± 23 <0.5
Chile Processing cultivar (tunnel grown) Green 303 ± 54 12.7
Fully ripe 712 ± 33 <0.5
Processing cultivar (tunnel grown) Green 364 ± 12 10.3
Fully ripe 768 ± 42 <0.5
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concentrated extract from tomato juice. On this basis, after a 
survey of available materials, cold break (low heat treatment), 
minimally processed tomato products were chosen as suit-
able starting materials for a high antiplatelet activity tomato 
extract. Once the starting material and its quality controls had 
been established, the Fruitflow® 1 and 2 extraction processes 
were designed and optimized, with reference to content of 
tAF and the three representative bioactives, in a way that 
directly optimized bioactivity. The key features of both pro-
cesses were control of time spent at high temperatures and the 
balance necessary to achieve the desired temperature profile 
while avoiding microbiological and waste issues. Fruitflow® 
1 is currently produced from cold break minimally processed 
tomato products (pastes, passatas, juices) in a 5-step process, 
which utilizes physical separation methods (centrifugation, 
filtration) at low temperatures to remove pulp and unwanted 
insoluble solids from the starting material, leading to a clear 
yellow juice. This is then concentrated by low-temperature 
evaporation and standardized for pH.
Fruitflow® 2 is a low-sugar derivative of Fruitflow® 1, 
deriving from the same raw material and using the same 
initial clarification processing steps. After removal of insol-
uble material, complex and simple sugars are extracted 
from the clarified tomato juice using an adsorption column 
process, in which the sugars which are the major constitu-
ents of tomato juice pass through a resin column without 
retention, while the remainder of the juice components 
are adsorbed from the juice and retained on the column. 
These retained components of interest—which can repre-
sent up to 2 % of the fresh weight of the tomato-derived 
starting material—are then recovered from the column, 
and the concentrate is dried to powder and standardized 
for moisture content. The resulting Fruitflow® 2 powder 
contains almost no sugars (glucose, fructose, pectin, starch 
or derivatives). The bioactive components are present in 
concentrations between 28–32 times higher than in Fruit-
flow® 1, due to the removal of the sugar and water matrix 
of the syrup ingredients. However, as the resin column used 
successfully retains the remainder of the tomato juice con-
stituents, the relative occurrence of these components in 
Fruitflow® 2 remains similar to that in Fruitflow® 1 (i.e., 
the process does not significantly alter the relative propor-
tions of the bioactive components).
An industrial specification for each ingredient ensures 
that the final product of each process is an extract whose 
antiplatelet activity against ADP, collagen, AA and TRAP 
in vitro is above a minimum level (Table 4) and as close 
to fresh tomato juice as possible. This specification is 
achieved by the monitoring of tAF and the three com-
pounds adenosine, chlorogenic acid and rutin, representa-
tives of F1, F2 and F3 in the fresh tomato. The specifica-
tion allows a standardized usage of the ingredients, so that 
Fruitflow® 1 and 2 may be used interchangeably depending 
on the application.
Table 3  Quantities of tAF 
components (shown separated 
into fractions F1, F2 and 
F3) isolated from a range of 
processed tomato products
The various tomato products were prepared by dilution with water, centrifugation and filtration to remove 
all insoluble materials, and freeze drying to yield dried soluble solids. The soluble solids were then 
redissolved in water and standardized to a set concentration before extraction of tAF using solid-phase 
extraction and separation of F1, F2 and F3 by semi-preparative reversed-phase HPLC. Values shown are 
expressed in μg g−1 product soluble solids and represent the mean quantities of F1, F2 and F3 isolated 
within product categories, together with the observed range for each category
* n = 10 products
Product F1 F2 F3
Mean Range Mean Range Mean Range
Fresh tomato extract 8095.6 n/a 410.3 n/a 1802.3 n/a
Commercial tomato paste* 6014.2 4211.8–7207.1 263.0 22.9–433.6 1176.3 945.5–1404.9
Commercial tomato soup* 3813.3 1089.1–5685.1 318.2 24.1–400.2 767.4 241.5–1586.6
Commercial tomato juice* 5661.5 5649.1–5692.0 84.0 54.5–99.3 1146.3 896.4–1377.9
Commercial tomato sauce* 4680.5 3599.8–5156.2 139.8 92.4–93.7 1155.8 823.8–1787.2
Fruitflow® 7874.6 n/a 389.2 n/a 2141.3 n/a
Table 4  Antiplatelet activity of the standardized Fruitflow® 1 and 
Fruitflow® 2 ingredients, expressed in terms of their IC50 values (mg 
Fruitflow/mL platelet-rich plasma) with regard to the major platelet 
agonists ADP, collagen, thrombin (thrombin receptor-activated pep-
tide, TRAP, used) and arachidonic acid
The IC50 in this context represents the amount of Fruitflow®, in mg 
dry matter, needed to inhibit platelet aggregation in 1 mL PRP by 
50 %, compared to control (saline) treatment. All values given are 
averages of triplicate measurements taken in PRP harvested from 10 
different platelet donors
IC50 ADP IC50 Collagen IC50 TRAP IC50 AA
Antiplatelet activity of the standardized Fruitflow® 1 and Fruitflow® 
2 ingredients, expressed as IC50 values
 Fruitflow® 1 <1.0 <1.0 <2.7 <3.6
 Fruitflow® 2 <0.05 <0.05 <0.5 <0.7
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The Fruitflow® 1 and 2 ingredients are now incorporated 
into a range of different food products, ranging from drinks 
to tablets. Both ingredients are stable in a wide variety of 
matrices, with appropriate shelf life in all, tested to industry 
standard ICH levels.
Human trials undertaken with Fruitflow® 1 
and Fruitflow® 2
Early studies
The first study which investigated the antiplatelet effects 
of a water-soluble tomato extract used freshly prepared 
tomato juice. As this juice was low in tAF concentration, 
a volume of 1L was given to ensure sufficient ingestion of 
tAF components. No significant effects could be observed 
in the small study group (n = 9, Fig. 4a). However, a 
second study using a crudely prepared prototype tomato 
extract concentrate, in which the subjects consumed 
approximately the same dose of bioactive compounds 
as in the 1L study, but in a much smaller volume (~10—
12 mL), did show an observable effect on platelet func-
tion at a variety of times after supplementation (Fig. 4b). 
It was concluded that tomato juice would be an inappropri-
ate vehicle for its antiplatelet compounds when attempting 
to achieve a systemic acute antiplatelet response via oral 
ingestion, and work began to refine the crude prototype 
already tested.
Main body of studies undertaken 
with standardized Fruitflow® 1 and Fruitflow® 2
After development of the Fruitflow® ingredients, and 
standardization of testing conditions, a unified set of 
studies was carried out to establish the efficacy of these 
novel ingredients ex vivo. A summary of the studies in 
which the standardized ingredients Fruitflow® 1 and 
Fruitflow® 2 have been used is given in Table 5. This 
table also allows comparison of the major outcomes of 
each of these studies, in terms of the extent of the anti-
platelet effects measured in comparison with the study 
baseline and to the study control. Studies which estab-
lished the onset time of an acute antiplatelet effect after 
oral ingestion of a dose of Fruitflow® 1 have been pub-
lished elsewhere [15]. These studies showed that in all 
subjects, an acute lowering of platelet aggregability to 
ADP and collagen was observed at a time three hours 
after consuming Fruitflow® (Table 5, #1). The range 
of onset times was from one and a half hours to three 
hours after consumption. In contrast, the normal diur-
nal increases in platelet aggregability were illustrated in 
subjects consuming the control supplement over the time 
Fig. 4  Summary of results from early-stage studies using tomato 
extract prototypes. a  % Change from baseline aggregation observed 
after ingestion of 1L freshly produced, filtered tomato juice, by 
healthy subjects (n = 9). This was a pilot study and was not placebo-
controlled. Changes from baseline aggregation in response to ADP 
and collagen were not significant. b  % Change from baseline aggre-
gation observed after consumption of either a prototype concentrated 
tomato extract or control extract for a period of two weeks. The study 
involved healthy subjects (n = 14). Changes from baseline aggrega-
tion in response to optimal ADP agonist (concentration used titred to 
give optimal platelet response in each sample) were significantly dif-
ferent from control at t = 2 weeks
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course measured. The persistence of this acute effect var-
ied between individuals, but in all cases platelet aggre-
gability returned to baseline 18 h after consumption of a 
single dose of Fruitflow® [68].
Size and variance of the acute antiplatelet effect
The range of acute antiplatelet effects observed in all 
studies undertaken is shown in Table 5. On average, 
these studies have shown an inhibition of the platelet 
response to ADP agonist of approximately 17–25 % and 
an inhibition of the response to collagen of approximately 
10–18 %. Arachidonic acid-induced platelet aggregation 
and thrombin receptor-activating peptide (TRAP)-induced 
platelet aggregation have also been shown to fall after 
Fruitflow® administration. A study in which Fruitflow® 1 
was administered to 93 healthy men and women (Table 5, 
#2) [16] showed that some variability in response may 
occur, with men responding more than women, and sub-
jects with higher risk factors for CVD responding more 
highly than others. A dose–response was established in 
studies administering different amounts of Fruitflow® 
1 (Table 5, #1); the shape of the dose–response curve is 
shown in Fig. 5. This dose–response work established that 
a dose of Fruitflow® equivalent to 65 mg tAF or approxi-
mately 3 average bowls of tinned tomato soup already 
caused close to the maximum level of platelet inhibition 
achievable by this extract and that no significant gain 
would be obtained in an acute setting from increasing the 
dose.
Effects of ingredient format and food matrix 
on the observation of antiplatelet effects
Two studies have been undertaken focusing on the two 
different ingredient formats, Fruitflow® 1 and Fruitflow® 
2, and the likelihood of matrix effects altering the acute 
antiplatelet response after consumption (Table 5, #4, #6). 
These studies, which involved 54 subjects, showed firstly 
that it was not possible to distinguish between the antiplate-
let effects observed for the Fruitflow® 1 and Fruitflow® 2 
ingredients, when consumed in doses of 3 g and 150 mg, 
respectively (Table 5, #4). No difference between the two 
ingredient formats could be detected three hours after con-
sumption. Secondly, the studies showed that incorporation 
of WSTC into water-based drinks, yoghurts and capsules 
was all viable means of inducing an antiplatelet effect three 
hours after consumption (Table 5, #6). The antiplatelet 
effects observed in all matrices were similar to those seen 
in previous studies (Table 5).
Effects of chronic consumption
Once the time of onset, persistence and size of effect related 
to a single dose had been established, studies examining 
the effects of continuous (i.e. daily) consumption of Fruit-
flow® were undertaken. These studies showed that the size 
of the antiplatelet effect observed after consuming a single 
dose of Fruitflow® daily for two or for four weeks was not 
significantly different from the size of effect observed after 
a single dose, that is, the observed effects were not cumula-
tive (Table 5, #3). Suppression of platelet function achieved 
through chronic consumption was continuous—measure-
ments of platelet function were taken in fasted subjects in 
the morning, approximately 24 h after consumption of their 
last Fruitflow® dose, and suppression of original baseline 
platelet function was observed after two and four weeks.
Safety considerations
Compounds found in Fruitflow® have been shown to affect 
many aspects of platelet function, including (via effects on 
TF immobilization and signalling) thrombin generation. 
Therefore, during all human intervention studies, care was 
taken to incorporate specific safety-focused measures to 
examine whether any effects on the intrinsic or extrinsic 
clotting pathways could be detected alongside antiplatelet 
effects. An antiplatelet which also affected blood coagu-
lation pathways could raise safety concerns. However, in 
all intervention studies undertaken, clotting time measure-
ments showed no significant increases from baseline levels 
(Table 5). Fruitflow® does not directly affect blood coagu-
lation at any dose tested.
Even without affecting blood coagulation directly, many 
antiplatelet drugs, taken on a chronic basis, give rise to 
excessive platelet inhibition and are associated with internal 
bleeding. These potentially serious side effects mean that 
antiplatelet therapy, a fundamental aspect of CVD second-
ary prevention, is contraindicated for primary prevention as 
the benefit conferred (lowering risk of a first CVD event in 
relatively low risk groups) is outweighed by the increased 
risk of gastric or intracranial bleeding [49]. This judgement 
was recently revisited by the US FDA, in the context of 
increasing obesity and type 2 diabetes mellitus levels in rel-
atively young populations, but was upheld [69]. The known 
side effects of existing antiplatelet drugs related to internal 
bleeding were clearly pertinent for consideration during 
Fruitflow® development. However, Fruitflow® differs fun-
damentally from antiplatelet drugs in the reversibility of its 
action. The widely used antiplatelet drugs have irreversible 
mechanisms of action. Over the course of ten days, approx-
imately 90 % of the circulating platelet population can be 
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irreversibly affected for the lifetime of those platelets. This 
level of platelet inhibition is then maintained by daily drug 
treatment. Conversely, the antiplatelet effects of Fruitflow® 
are not irreversible, or cumulative, and can be overcome by 
increased agonist concentrations. This very significant dif-
ference in mode of action renders Fruitflow® suitable for 
use by the general population as a dietary functional ingre-
dient, while antiplatelet drugs cannot be used.
As Fruitflow® is designed as a food ingredient, with 
potential for incorporation into a variety of food products, a 
specific study was undertaken to examine the likely effects 
of overconsumption (Table 5, #5). As the amount of Fruit-
flow® in any one food product serving is low, equivalent 
to approximately three bowls of tinned tomato soup, and 
as dose–response studies had shown that increasing the 
dose significantly would not result in a much bigger acute 
effect on platelets, no significant dangers were anticipated. 
The results of the study confirmed this position; drinking 
1L of a drink containing four daily doses of Fruitflow® did 
not dangerously reduce platelet aggregability compared 
to baseline. In fact, the reduction in platelet functional-
ity observed was rather less than that observed for a sin-
gle serving of the same product. This underlines again the 
effects of food volume on observable systemic antiplatelet 
effects.
Comparing the dietary antiplatelet Fruitflow® 
with the antiplatelet drug aspirin
A study comparing a single dose of Fruitflow® with 75 mg 
aspirin, either as a single dose or taken continuously 
for one week, was undertaken in order to benchmark the 
effects of a dietary antiplatelet (Table 5, #7). A comparison 
of the effects of Fruitflow® and aspirin on the platelet pro-
teome was first carried out, to examine similarities and dif-
ferences in mechanisms of action. This comparison showed 
that aspirin and Fruitflow® affect broadly similar proteomic 
pathways, with aspirin affecting the signalling pathways 
more strongly than Fruitflow®—assuming full metabolism 
of the entire ingested dose. Proteins affected by Fruitflow® 
and aspirin are associated with platelet structure, plate-
let coagulation, platelet membrane trafficking and platelet 
secretion - actin-binding proteins, fibrinogen beta chain 5, 
Ras-related proteins, redox system proteins and HSP70s. 
Of the 26 proteins with altered expression after treat-
ment, 11 were affected by both Fruitflow® and aspirin, 14 
by aspirin alone and one by Fruitflow® alone. The single 
protein affected only by Fruitflow® was identified as PDI, 
known to disrupt inside-out signalling as described earlier.
The intervention study which followed in 47 healthy 
subjects showed that the effects of a single dose of 
Fig. 5  Dose–response curve 
at t = 3 h after ingestion of 
Fruitflow® 1 at different dosage 
levels, in 23 subjects (Study 
#2, Table 5). Dose 2 tomatoes 
represents a single dose of 
Fruitflow® 1 corresponding to 
65 mg tAF components, while 
dose 6T represents a three doses 
corresponding to 195 mg tAF 
components. Data shown for 
dose 8 tomatoes (corresponding 
to 260 mg tAF components) 
are extrapolated from the curve 
generated
475Eur J Nutr (2017) 56:461–482 
1 3
Fruitflow® were similar, in terms of antiplatelet action, 
effects on thromboxane synthesis and time to form a pri-
mary haemostatic clot (PFA-100 closure time), to those of 
a single 75 mg dose of aspirin (Table 5, #7). When aspi-
rin was taken daily for seven days, the associated increase 
in PFA-100 closure time was three times higher than that 
associated with a single aspirin dose. The cumulative anti-
platelet effect of aspirin when taken daily is well known 
and reflects its irreversible disabling of platelet COX-1 and 
associated signalling. Fruitflow®’s effects are not cumula-
tive in this way, as its effects do not irreversibly disable 
platelet signalling pathways. Thus, taking the results for the 
study population as a whole, daily aspirin supplementation 
may be viewed as approximately three times as efficacious 
as daily Fruitflow® supplementation, due to the irreversibil-
ity of its action. This overall result seemed to echo the pro-
teomic data, but further examination showed that it masked 
some interesting behaviour in study subgroups. The anti-
platelet effects of aspirin in healthy subjects are extremely 
heterogeneous, with some subjects experiencing a very 
large increase in time to form a primary haemostatic clot, 
while others respond poorly (Fig. 6). Approximately 50 % 
of aspirin responders had a response to the drug which was 
lower than the average response for the treatment group, 
in terms of time to form a primary haemostatic clot. This 
group of subjects had a residually strong response to col-
lagen after 7 days of aspirin treatment, and over one-third 
of the group responded better to Fruitflow® supplementa-
tion than to 7-day aspirin supplementation. At the other end 
of the spectrum, for 18 % of the study population, taking 
aspirin for 7 days more than trebled the time to clot. This 
underlines the reasons behind the known internal bleeding 
risks associated with aspirin and its unsuitability for use 
in primary prevention. While the response to Fruitflow®, 
in terms of time to clot data, was also heterogeneous, it 
was markedly less so than the response to aspirin (Fig. 6). 
The majority of the subject group experienced increases in 
time to form a primary haemostatic clot of up to twofold, 
with less subjects at either extreme. It would appear that 
the proteomic predictions of stronger aspirin-led effects on 
platelet signalling may not be observed ex vivo, possibly 
due to wide variability in the extent of aspirin metabolism, 
but also possibly due to differences in the relative impor-
tance of platelet collagen signalling pathways between 
individuals. Fruitflow®, with its wider range of antiplate-
let compounds, may have a less variable metabolism and 
thus achieve its more moderate effects more widely. These 
more moderate effects, which can be related to the revers-
ibility of the antiplatelet action of Fruitflow® rather than its 
mode of action per se, render it a possible option for use 
in primary prevention of CVD, in contrast to aspirin at any 
dosage. However, outcomes-based studies on dietary sup-
plements such as Fruitflow® are needed before their true 
potential can be properly assessed.
EFSA approval of Fruitflow® and its 
commercialization in different countries
In 2006, the European Union (EU) adopted a regulation 
on the use of nutrition and health claims for foods which 
lays down harmonized EU-wide rules for the use of health 
or nutritional claims on foodstuffs (Regulation (EC) No 
1924/2006). One of the key objectives of this regulation is 
to ensure that any claim made on a food label in the EU is 
clear and substantiated by scientific evidence. Different cat-
egories of claim are defined. Health claims are defined as 
pertaining to relationships between food and health either 
with regard to a function of the body (Article 13 claims), 
or with regard to reducing a risk factor for a disease (Arti-
cle 14a claims), or with regard to children’s development 
(Article 14b claims). Nutrient claims are defined as per-
taining to foods with particular nutritional properties with 
regard to either the energy, or the nutrients, they provide. 
Allowed nutrient claims are clearly defined within the 
regulation. However, companies wishing to associate their 
food or ingredient with a health claim must submit a dos-
sier in support of the desired claim, which is then assessed 
by the EFSA Panel on Dietetic Products, Nutrition and 
Allergies. Key to the dossier is the inclusion of human 
intervention studies showing evidence of the health ben-
efit claimed, for the food/ingredient of interest. More than 
2,200 unique claims have been submitted for assessment to 
date, of which over 95 % have been Article 13 claims, with 
an overall approval rate of close to 10 %. The first Article 
13 claim based on newly developed evidence or proprietary 
data [a special category under Article 13(5)] to be achieved, 
in December 2009, was for Fruitflow®, when the EU Com-
mission authorized the health claim “water-soluble tomato 
concentrate (WSTC) I and II helps maintain normal plate-
let aggregation, which contributes to healthy blood flow”. 
The authorized claim was based on the eight human stud-
ies (seven proprietary), and seven non-human studies (three 
proprietary), conducted with Fruitflow®, which is given in 
Table 5.
Thus, Fruitflow® is now authorized by EFSA for daily 
consumption, with the conditions that 3 g Fruitflow® 1 or 
150 mg Fruitflow® 2 must be included in either foods (e.g. 
fruit juices, flavoured drinks or yoghurt drinks with a total 
volume up to 250 mL), or in powdered, tabletted or encap-
sulated food supplements (to be taken with up to 250 mL 
water).
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New functionalities of Fruitflow®: 
Anti‑inflammatory and blood pressure‑lowering 
effects
Atherosclerosis is considered as a chronic inflammatory 
disease of the arterial vessel wall and is a major cause of 
mortality and morbidity in the world [70–72]. Inflamma-
tion plays a critical role in the initiation and progression 
of atherosclerosis; it involves the recruitment of inflam-
matory cells from the circulation and their transmigration 
through the endothelial wall, resulting in vascular damage, 
narrowing and hardening of the arteries [71]. The intake 
of tomatoes and tomato products has been associated with 
a decreased risk of chronic inflammatory diseases such 
as atherosclerosis and is linked with a healthy Mediterra-
nean diet [1, 33, 73]. Moreover, several in vitro animal and 
human studies have shown that tomato concentrates and 
phytochemicals from tomato have anti-inflammatory activi-
ties and may reduce the risk of CVD [73–78].
Activation of the inflammatory pathways in mac-
rophages plays a critical role in the initiation and progres-
sion of endothelial dysfunction which eventually results 
in atherosclerosis. The influence of Fruitflow® on the 
inflammatory response of macrophages and on endothe-
lial dysfunction in human umbilical vein endothelial cells 
(HUVEC) has recently been investigated [18]. In this 
study, Fruitflow® was able to regulate the production of 
cytokines and interleukins in LPS-stimulated macrophages. 
It decreased the production of pro-inflammatory cytokines 
(TNF-α, IL-1β and IL-12), while the production of the anti-
inflammatory IL-10 was increased. Consequently, Fruit-
flow® reduced the production of inflammatory mediators 
related to chronic inflammation. Nuclear factor-κB (NF-
κB) is an important pro-inflammatory transcription factor, 
and its activation is involved in the pathology of vascular 
inflammatory diseases. Gene expression analysis indicated 
that Fruitflow® reduced the expression levels of NF-κB, 
suggesting that Fruitflow® regulated the gene expression of 
inflammatory mediators via the NF-κB pathway. The data 
are in agreement with the recent publication from Navar-
rete et al. [79] which investigated the effects of an aque-
ous extract of tomato (produced in a similar manner to the 
laboratory-scale aqueous extracts described here) on the 
expression of pro-inflammatory cytokine in LPS-activated 
monocyte-derived THP-1 macrophages. The Navarrete 
aqueous tomato extract was shown to inhibit the expression 
of cytokines (TNF-α, IL-1β) and the activation of NF-κB 
in the LPS-stimulated macrophages. Intercellular adhe-
sion molecule-1 (ICAM-1) and vascular cell adhesion mol-
ecule-1 (VCAM-1) are two critical adhesion molecules that 
are expressed on endothelial cells and mediate adhesion of 
leucocytes and their interactions with inflamed endothelial 
cells leading to endothelium damage [80]. Activation of the 
endothelial cells and the production of inflammatory medi-
ators by atherosclerotic lesions results in the up-regulation 
of the adhesion molecules (ICAM-1, VCAM-1). Thus, 
ICAM-1 and VCAM-1 are considered as early markers of 
endothelial dysfunction and atherosclerosis. In the Schwa-
ger et al study (2016), Fruitflow® significantly decreased 
the production and the gene expression of ICAM-1 and 
VCAM-1 in activated HUVEC. This suggests that Fruit-
flow® may be capable of altering some of the pathologies 
typically seen in endothelial dysfunction. Tomato is a rich 
source of lipophilic and hydrophilic phytochemicals which 
could influence the inflammatory response [73]. Fruitflow® 
is standardized using three “natural” constituents: adeno-
sine, chlorogenic acid and rutin, which are representative 
of the three main groups of active constituents and have 
been shown to inhibit both platelet aggregation and inflam-
matory pathways. Adenosine has been suggested to play a 
role in immune and inflammatory processes and to improve 
various inflammatory diseases [81–84]. Chlorogenic acid is 
a polyphenol with anti-inflammatory activity, which inhib-
its the LPS-triggered activation of NF-κB and the associ-
ated inflammatory response [85, 86]. In macrophages, rutin 
suppressed oxidative stress and modulated the gene expres-
sion of mediators involved in chronic inflammation [87, 88] 
[89]. Collectively, the data indicate that compounds con-
tained in Fruitflow® have the capacity to modulate signal-
ling pathways which alter vascular function, the develop-
ment of atherosclerotic lesions and consequently the risk of 
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up to 3-fold more than 3-fold 
Fig. 6  Increases in PFA-100 closure time by aspirin and Fruitflow®. 
Time to form a primary clot after treatment with either 7d aspirin 
(top) or Fruitflow® (bottom) was determined. The proportions of the 
study population experiencing less than twofold, up to twofold and 
over threefold increases in time to form primary clot are shown, illus-
trating the heterogeneity of the responses observed
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effects. The extent to which such pathways can be affected 
in humans after ingestion of Fruitflow® is not yet known 
and could form an interesting topic for future stud-
ies. Figure 7 summarizes the effects of Fruitflow® on the 
endothelial response to inflammatory stimuli via different 
mechanisms such as activation of NF-κB and the up-regu-
lation of adhesion molecules.
Hypertension is another very important risk factor for 
CVD including coronary heart disease, stroke, conges-
tive heart failure and peripheral vascular disease [90]. 
Clinically, hypertension is characterized by abnormally 
high blood pressure with the systolic reading greater than 
140 mmHg and diastolic reading greater than 90 mmHg. 
Lowering blood pressure has been linked to 35 %–40 % 
reductions in the incidence of stroke, 20 %–25 % in myo-
cardial infarction and up to 50 % in heart failure, making 
hypertension a strong target for therapeutic intervention. 
Because dietary changes are a first-line intervention for 
hypertension, food products themselves are increasingly 
under consideration for the specific effects they may have 
on blood pressure. In recent years, there has been con-
siderable interest in the potential for using natural food 
components as functional foods to treat hypertension, 
especially for people with borderline to mild high blood 
pressure that does not warrant the prescription of antihy-
pertensive drugs. Increasingly, nutraceuticals and food 
products have been investigated for their effects on hyper-
tension. Polyphenols inhibit and down-regulate expression 
of angiotensin-converting enzyme (ACE) and renin. In 
addition, polyphenols have also been associated with the 
formation of endothelial nitric oxide leading to vasodila-
tion and lowering of blood pressure. The renin–angioten-
sin system is a powerful mechanism for controlling blood 
pressure [91, 92]. In hypertensive patients with elevated 
plasma rennin–angiotensin activity, a fivefold increased 
incidence of myocardial infarction was demonstrated [93]. 
ACE (EC 3.4.15.1, dipeptidyl carboxypeptidase) is a gly-
coprotein peptidyldipeptide hydrolase that cleaves histidyl 
leucine dipeptide from angiotensin I forming the potent 
vasoconstrictor angiotensin II. Studies demonstrated that 
ACE inhibitors (ACEIs) significantly reduced the mor-
bidity and mortality in patients with myocardial infarc-
tion and the incidence of ischaemic events in patients with 
CVD, even in the absence of their blood pressure-lowering 
effects [94–96]. The therapeutic administration of certain 
ACEIs has also been associated with positive health effects 
beyond the regulation of blood pressure [97]. Polyphenols 
inhibit and down-regulate expression of ACE and renin 
[98]. Tomato juice was earlier shown to lower blood pres-
sure in human volunteers, and this effect was thought to 
be associated with its high antioxidant content [99, 100]. 
We therefore tested whether Fruitflow® inhibited human 
serum ACE activity and rabbit lung ACE activity [17]. The 
IC50 value of Fruitflow
® for ACE inhibition in serum was 
1.91 ± 0.24 mg/ml (0.038 μg catechin equivalent(CE)/
ml), whereas for captopril, the value was 0.56 ± 0.08 μg/
ml. Fruitflow® also inhibited rabbit lung ACE activity in 
a dose-dependent manner. Orange or banana extract had 
no such anti-ACE activity. Flavonoid-rich plant extracts 
have been demonstrated as natural competitive ACEIs 
where the ACE activity is identified as a critical factor 
in regulating high blood pressure. These compounds are 
known to be inhibitors of cyclic nucleotide phosphodies-
terase and TxA2 synthesis, two main determining factors 
in human blood platelet activation/aggregation processes. 
Consequently, it is possible that the consumption of these 
bioactive components of Fruitflow® might reduce more 
than one CVD risk factor, such as platelet hyperactivity 
and hypertension. As yet, these data are based on in vitro 
experiments, and it is clear that further work is required 
to provide clear information on the metabolic fate of these 
compounds, and the dosage required for physiological 
benefits. While a functional food approach offers interest-
ing possibilities for cardio-protection, the requirement for 
long-term randomized controlled trials remains. Advances 
in the knowledge of both platelet biology and the mecha-
nism of action of Fruitflow® bioactive compounds will 
provide new avenues to develop dietary strategies aimed at 
promoting cardiovascular health.
Fruitflow® and other platelet inhibiting food 
ingredients
Nutritional modification of cellular functions by dietary 
lipids and other nutritive and non-nutritive factors offers 
an attractive avenue to correct, modify or prevent many 
pathophysiological processes including platelet hyperac-
tivity [101]. The mediation of such effects is thought to be 
primarily achieved through alterations of cell membrane 
composition and other endogenous lipid stores, with a 
consequent reduction in AA-derived eicosanoid produc-
tion and modification of the functional activity of various 
receptors on platelet membranes [101]. Eicosapentaenoic 
acid, 20:5n-3 (EPA) and DHA substitute biologically less 
potent eicosanoids, while the non-nutritive compounds 
act to reduce all eicosanoid formation specially TxA2, an 
important platelet-aggregating agent. Numerous epidemio-
logical studies and clinical trials have reported the health 
benefits of different omega 3 polyunsaturated fatty acids 
(PUFAs), including a lower risk of coronary heart diseases 
[102]. There are several reviews available on the effects of 
alpha-linolenic (ALA), EPA and docosahexaenoic, 22:6n-3 
(DHA) acids on some risk factors associated with athero-
thrombosis, including platelet activation, plasma lipid con-
centrations and oxidative modification of LDL [102, 103]. 
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The role of platelets in haemostasis and thrombosis has 
been known for a long time and is well defined, but more 
recently a new concept has emerged stating that plate-
lets play a central role in the atherothrombotic process [9, 
10]. Dyerberg and Bang showed that Inuits had attenuated 
platelet reactivity [104] as they consumed omega 3 fatty 
acids. Platelet aggregation response was diminished with 
omega 3 fatty acids consumption [105–107]. A meta-anal-
ysis conducted by Gao et al. [108] has demonstrated that 
omega 3 PUFAs are associated with a significant reduc-
tion in platelet aggregation. In addition, low intake of EPA 
may reduce platelet aggregation, without changing the fatty 
acid platelet composition [109, 110]. In the same way, fol-
lowing supplementation with DHA [111] platelet function 
was reduced and a retroconversion of DHA into DPA and 
EPA was evidenced. More recently, a dose–response study 
with middle-aged healthy volunteers ingesting increas-
ing amounts of DHA indicated that platelet reactivity was 
decreased after 400 and 800 mg DHA/day [112]. It is dif-
ficult to attribute precisely the effects to each fatty acid, and 
their beneficial and complementary effects could well be 
linked to formation or diminution of specific eicosanoids 
and/or docosanoids.
Combinations of antiplatelet drugs are known to have dif-
ferent physiological effects than single agents. Taking a sim-
ilar strategy from a functional food perspective, a combina-
tion of tomato extract with antiplatelet activity [13] and n-3 
fatty acids was investigated for effects on platelet aggrega-
tion in vitro. The combination of tomato extract and omega 
3 fatty acids inhibited in vitro platelet aggregation to a 
greater extent than either alone, and this inhibition was cor-
related with intracellular platelet cAMP levels [113]. Such 
data indicate that combinations of Fruitflow® and omega 3 
fatty acids—and potentially other non-nutritive compounds 
such as resveratrol and other polyphenols—may be effective 
in improving platelet function. Further human intervention 
studies should be conducted in order to determine the scale 
of benefits which may arise following consumption of Fruit-
flow® combined with other bioactive substances.
Conclusions
This review provides information that substantiates the 
cardio-protective claims of Fruitflow®. Normal platelet 
activity is the key for the maintenance of haemostasis and 
Fig. 7  Fruitflow® inhibits the activation of macrophage and endothe-
lial cells via different mechanisms. The endothelium reacts to inflam-
matory stimuli derived from activation of cytokines such as NF-κB, 
and the up-regulation of adhesion molecules (ICAM, VCAM), which 
play a role in leucocyte adhesion and transmigration across the 
endothelial layer. NF-κB is a key transcription factor which induces 
the release of pro-inflammatory mediators (cytokines, chemokines 
and adhesion molecules) that further promote vascular inflamma-
tion leading to the initiation and development of atherosclerosis. 
This Fruitflow® inhibits the activation of macrophage and endothelial 
cells, which could help to reduce leucocyte recruitment and promote 
a reduction in tissue inflammation
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normal blood flow. Hyperactive platelets interact with ves-
sel walls by shedding macro-particles, secreting several 
adhesive growth factors, and inflammatory agents interrupt 
the blood flow and produce a pro-thrombotic state in people 
with obesity, diabetes, a sedentary lifestyle or hypertension, 
and in people who smoke. In general, the molecular events 
underpinning these processes are broadly similar. It has 
long been known that disturbances in blood flow, changes 
in platelet reactivity and enhanced coagulation reactions 
facilitate pathological thrombus formation, and the mainte-
nance of normal platelet activity is critical to overall hae-
mostasis. Fruitflow® developed from tomato containing 
bioavailable cardio-protective compounds can be of ben-
efit to the people who are vulnerable to develop CVD. The 
outlined data suggest that Fruitflow® may be useful in the 
primary prevention of CVD. An array of extensive basic, 
mechanistic, compositional and several human trials are 
testimony to its cardio-protective benefits.
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